Occurrence of ESBL & Amp-C β-lactamases & susceptibility to newer antimicrobial agents in complicated UTI

Indian Journal of Medical Research

Volumn 127, Issue 1, 2008, Pages 85-88

  Taneja, Neelam ^a   Rao, Pooja ^a   Arora, Jitender ^a   Dogra, Ashok ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

AmpC lactamases; Drug resistance; ESBL; Uropathogens

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; AZTREONAM; BETA LACTAMASE AMPC; CEFEPIME; CEFTAZIDIME; CEFTAZIDIME PLUS CLAVULANIC ACID; CLAVULANIC ACID; EXTENDED SPECTRUM BETA LACTAMASE; IMIPENEM; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATION; ENTEROBACTER AEROGENES; ESCHERICHIA COLI; KLEBSIELLA; NONHUMAN; PSEUDOMONAS AERUGINOSA; URINARY TRACT INFECTION; URINE CULTURE;

ANTI-BACTERIAL AGENTS; AZTREONAM; BACTERIAL PROTEINS; BETA-LACTAMASES; CEPHALOSPORINS; DRUG RESISTANCE, BACTERIAL; HUMANS; PENICILLANIC ACID; PIPERACILLIN; PROSPECTIVE STUDIES; URINARY TRACT INFECTIONS;

EID: 43449096370     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Gales AC, Jones RN, Gordon KA, Sader HS, Wilke WW, Beach ML, et al. Activity and spectrum of 22 antimicrobial agents tested against urinary tract pathogens in hospitalised patients in Latin America: report from the second year of the SENTRY Antimicrobial Surveillance Program (1998). J Antimicrob Chemother 2000; 45: 295-303.
2. Gupta K, Sahm DF, Mayfield D, Stamm WE. Antimicrobial. resistance among uropathogens that cause community-acquired urinary tract infections in women: A nationwide analysis. Clin Infect Dis 2001; 33: 89-94.
3. Jarlier V, Nicolas M H, Fournier G, Philippon A. Extended broad-spectrum β-lactamases conferring transferable resistance to newer βlactam agents in enterobacteriaceae: Hospital prevalence and susceptibility patterns. Rev Infect Dis 1988; 10: 867-78.
4. Phillippon A, Arlet O, Jacoby GA. Plasmid-determined AmpC-type β-lactamases. Antimicrob Agents Chemother 2002; 46: 1-11.
5. Fukuda H, Hiramatsu K. Mechanisms of endogenous drug resistance acquisition by spontaneous chromosomal gene mutation. Nippon Rinsho 1997; 55: 1185-90.
6. Anananthan S, Subha A. Cefoxitin resistance mediated by a loss of a porin in clinical strains of Klebsiella pneumoniae and E. coli. Indian J Med Microbiol 2005; 23: 20-3.
7. Black JA, Moland ES, Thomson KS. AmpC disk test for detection of plasmid-mediated AmpC- β lactamases in Enterobacteriaceae lacking chromosomal AmpC- β lactamases. J Clin Microbiol 2005; 43: 3110-3.
8. Bush K, Jacoby GA, Medeiros AA, A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995; 39: 1211-33.
9. Khurana S, Taneja N, Sharma M; Extended spectrum beta-lactamase mediated resistance in urinary tract isolates of family Enterobacteriaceae. Indian J Mel Res 2002; 116: 145-9.
10. Collee JG, Miles RS, Watt B. Tests for the indentification of bacteria. In: Collee JG, Fraser AG, Marmion BP, Simmons A, editors. Mackie & MacCartney practical medical microbiology, 14th ed. Edinburgh: Churchill Livingstone; 1996. p. 151-79.
11. National Committee for Clinical Laboratory Standards (2000). Performance standards for antimicrobial susceptibility testing-Ninth information supplement: M100-S10. NCCLS. Wayne, PA, USA.
12. Sanders CC, Sanders WE, Goering HV. In vitro antagonism of β-lactam antibiotics by cefoxitin. J Antimicrob Chemother 1982; 21: 968-75.
13. Manchanda V, Singh NP. Occurrence and detection of AmpC β-lactamases among Gram negative clinical isolates using a modified three-dimensional test at Guru Tegh Bahadur Hospital, Delhi, India. J Antimicrob Chemother 2003; 51: 415-8.
14. Coudron P, Moland E, Thomson KS. Occurrence and detection of AmpC β-lactamase among Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis isolates at a Veterans Medical Centre. Clin Microbiol 2000; 38: 1791-6.
15. Livermore DM. β-lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995; 8: 557-84.
16. Thomson KS, Moland ES. Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2001; 45: 3548-54.
17. Zahetti G, Bally F, Greub G, Garbino J, Kinge T, Lew D, et al. Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multi-center, evaluator-blind, prospective, randomized study. Antimicrob Agents Chemother 2003; 47: 3442-7.